Clinical trialNCT01382719CompletedPhase 2Interventional

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

SponsorPalatin Technologies, IncEnrollment612Female Sexual Arousal DisorderHypoactive Sexual Desire Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jeffrey Edelson, MD, FRCPC
Palatin Technologies, Inc
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

68 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Site 4
North Vancouver, British Columbia, Canada
Site 41
Barrie, Ontario, Canada
Site 21
Burlington, Ontario, Canada

United States

Site 56
Birmingham, Alabama, United States
Site 26
Huntsville, Alabama, United States
Site 64
Mobile, Alabama, United States
Site 45
Chandler, Arizona, United States
Site 39
Phoenix, Arizona, United States
Site 25
Tucson, Arizona, United States
Site 78
Hot Springs, Arkansas, United States
Site 16
Jonesboro, Arkansas, United States
Site 52
National City, California, United States
Site 73
Newport Beach, California, United States
Site 80
Sacramento, California, United States
Site 12
San Diego, California, United States
Site 37
Denver, Colorado, United States
Site 40
Lakewood, Colorado, United States
Site 8
Avon, Connecticut, United States
Site 75
Farmington, Connecticut, United States
Site 33
New London, Connecticut, United States
Site 32
Washington D.C., District of Columbia, United States
Site 10
Aventura, Florida, United States
Site 27
Fort Myers, Florida, United States
Site 66
Melbourne, Florida, United States
Site 61
Orlando, Florida, United States
Site 1
West Palm Beach, Florida, United States
Site 82
Atlanta, Georgia, United States
Site 55
Decatur, Georgia, United States
Site 70
Chicago, Illinois, United States
Site 54
Peoria, Illinois, United States
Site 63
South Bend, Indiana, United States
Site 13
Wichita, Kansas, United States
Site 48
Lexington, Kentucky, United States
Site 57
Zachary, Louisiana, United States
Site 9
Baltimore, Maryland, United States
Site 60
Rockville, Maryland, United States
Site 74
St Louis, Missouri, United States
Site 35
Lincoln, Nebraska, United States
Site 24
Las Vegas, Nevada, United States
Site 72
Las Vegas, Nevada, United States

28 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bremelanotide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2011
Primary completion: 30 Sept 2012
Completion: 30 Sept 2012
Last update posted: 18 Dec 2014
Registered enrollment: 612
Registry id: NCT01382719

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.